ArticleFrontiers in microbiology2025
Enhanced nattokinase production by
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Optimization of Solid-State Fermentation Process for Prodigiosin Production from Soybean Residue UsingMicroorganisms · 2026Article
- Enhanced production of Nattokinase by Bacillus aryabhattai RP6 isolated from fermented Brassica oleracea.BMC biotechnology · 2026Article
- Enhanced nattokinase production by optimized fermentation conditions of douchi-derived Bacillus subtilis natto NK11 and evaluation of its thrombolytic activity.Antonie van Leeuwenhoek · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nattokinase is an alkaline serine protease with potent thrombolytic activity. Due to its safety profile, low cost, and ease of oral administration, it has gained significant attention for therapeutic applications. To meet the demand for cost-effective production of nattokinase via fermentation, this study utilized renewable biomass resources-glycerol and okara-as raw materials for nattokinase production. Methods: A metabolic pathway for efficient glycerol utilization in Bacillus subtilis 13,932 was engineered using genetic modifications. The co-expression of glpF and glpK significantly enhanced the strain's ability to metabolize glycerol. Building upon this, fermentation conditions using glycerol as the carbon source and okara as the nitrogen source were optimized. A Box-Behnken Design was employed to determine the optimal medium composition. Additionally, fermentation parameters were further optimized through a single-factor experiment. Results: The optimal medium composition was determined to be: glycerol 23 g/L, okara 96 g/L, MgSO Discussion: The genetic modifications enabling efficient glycerol metabolism in Bacillus subtilis 13,932, along with the optimized fermentation strategy using renewable resources, significantly improved nattokinase production. The high enzymatic activity achieved demonstrates the potential of this approach for cost-effective and sustainable nattokinase production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.